Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) designed to stimulate the pituitary gland to increase growth hormone (GH) secretion. It is modified for extended half-life, often by binding to albumin, which allows less frequent dosing compared with native GHRH. Commonly discussed effects include increased GH and IGF-1 levels, potential improvements in lean body mass, recovery, and fat metabolism. Side effects may include water retention, joint pain, numbness or tingling, and increased appetite; long-term safety and efficacy in humans remain under investigation. CJC-1295 is typically used in research settings and is not approved by regulatory authorities for general clinical use.
CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) designed to stimulate the pituitary gland to increase growth hormone (GH) secretion. It is modified for extended half-life, often by binding to albumin, which allows less frequent dosing compared with native GHRH. Commonly discussed effects include increased GH and IGF-1 levels, potential improvements in lean body mass, recovery, and fat metabolism. Side effects may include water retention, joint pain, numbness or tingling, and increased appetite; long-term safety and efficacy in humans remain under investigation. CJC-1295 is typically used in research settings and is not approved by regulatory authorities for general clinical use.